- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Jefferson City Today
By the People, for the People
Missouri Lawmakers Debate Psychedelic Clinical Trials
Proposed legislation could allow use of psilocybin and ibogaine for certain veterans and first responders.
Mar. 31, 2026 at 2:49am
Got story updates? Submit your updates here. ›
Proposed legislation in Missouri could allow clinical trials of psychedelic treatments for certain veterans and first responders.Jefferson City TodayThe Missouri House is set to approve legislation that could establish in-state clinical trials for the use of psilocybin and ibogaine, two psychedelic substances, to treat certain mental health conditions in eligible veterans and first responders. The bill outlines specific criteria for who would qualify for the treatments, as well as guidelines for administration.
Why it matters
This legislation represents a growing interest in exploring the potential therapeutic benefits of psychedelics, particularly for populations like veterans and first responders who face high rates of mental health challenges. If passed, it could pave the way for further research and access to these treatments in Missouri.
The details
House Bill 1717 would allow the use of psilocybin and ibogaine, which are currently classified as Schedule I drugs by the federal government, in clinical trials for eligible patients. To qualify, individuals must be 21 or older, suffer from PTSD, major depression, substance use disorder, or require end-of-life care, and enroll in a study approved by the Department of Mental Health. The bill also outlines requirements for facilitators who would administer the substances and guidelines for testing the psilocybin.
- The Missouri House is set to approve the legislation in the coming weeks.
The players
Missouri House
The lower chamber of the Missouri state legislature that is expected to approve the psychedelic clinical trials legislation.
What’s next
If the bill passes the House, it will move to the Missouri Senate for consideration.
The takeaway
This proposed legislation reflects a growing interest in exploring the potential therapeutic benefits of psychedelics, particularly for populations facing high rates of mental health challenges. If passed, it could pave the way for further research and access to these treatments in Missouri.
